Literature DB >> 27100493

The PI3K/AKT pathway in the pathogenesis of prostate cancer.

Huixing Chen1, Lan Zhou2, Xiaorong Wu3, Rongbing Li2, Jiling Wen2, Jianjun Sha3, Xiaofei Wen4.   

Abstract

Despite recent advances in our understanding of the biological behavior of prostate cancer (PCa), PCa is becoming the most common malignancy in men worldwide. The phosphatidylinositol 3-kinase (PI3K)/AKT pathway has been implicated in prostate carcinogenesis. Inflammatory cytokines (CCR9, IL-6, and TLR3) regulate PI3K/AKT signaling during apoptosis of PCa cells, and PI3K/AKT signaling participates with androgen-, 1alpha,25(OH)2-vitamin D3-, and prostaglandin-associated mechanisms and is regulated by ErbB, EGFR, and the HER family during cell growth. During metastasis of PCa cells, the PI3K/AKT/NF-kappaB/BMP-2-Smad axis, PTEN/PI3K/AKT pathway, and PI3K/AKT/mTOR signaling regulates tumor cell metastasis and invasion. The present review focuses on the PI3K/AKT signal pathway and discusses the role of the PI3K/AKT signal pathway in PCa tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27100493     DOI: 10.2741/4443

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  65 in total

1.  Downregulation of monocarboxylate transporter 1 inhibits the invasion and migration through suppression of the PI3K/Akt signaling pathway in human nasopharyngeal carcinoma cells.

Authors:  Pei Zhang; Jie Ma; Jiao Gao; Fang Liu; Xiaojin Sun; Fang Fang; Surong Zhao; Hao Liu
Journal:  J Bioenerg Biomembr       Date:  2018-06-07       Impact factor: 2.945

Review 2.  Role of androgen receptor splice variants, their clinical relevance and treatment options.

Authors:  S Wach; H Taubert; M Cronauer
Journal:  World J Urol       Date:  2019-01-19       Impact factor: 4.226

3.  Smad4 induces cell death in HO-8910 and SKOV3 ovarian carcinoma cell lines via PI3K-mTOR involvement.

Authors:  Yushuang Yao; Zhe Zhang; Fanmao Kong; Zhuqing Mao; Zhaoyuan Niu; Chuan Li; Aiping Chen
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-10

4.  Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes.

Authors:  Matthew Utter; Sohag Chakraborty; Limor Goren; Lucas Feuser; Yuan-Shan Zhu; David A Foster
Journal:  Cancer Lett       Date:  2018-03-08       Impact factor: 8.679

5.  Activation of Notch pathway is linked with epithelial-mesenchymal transition in prostate cancer cells.

Authors:  Lianhua Zhang; Jianjun Sha; Guoliang Yang; Xuyuan Huang; Juanjie Bo; Yiran Huang
Journal:  Cell Cycle       Date:  2017-04-07       Impact factor: 4.534

6.  Cabazitaxel suppresses the proliferation and promotes the apoptosis and radiosensitivity of castration-resistant prostate cancer cells by inhibiting PI3K/AKT pathway.

Authors:  Zheng Xu; Luwei Xu; Yuzheng Ge; Hongbin Sun; Jiageng Zhu; Quanliang Dou; Ruipeng Jia
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

7.  Leelamine suppresses cMyc expression in prostate cancer cells in vitro and inhibits prostate carcinogenesis in vivo.

Authors:  Krishna B Singh; Eun-Ryeong Hahm; Shivendra V Singh
Journal:  J Cancer Metastasis Treat       Date:  2021-03-26

8.  Resveratrol Downregulates miR-155-5p to Block the Malignant Behavior of Gastric Cancer Cells.

Authors:  Nana Su; Lanlan Li; Erle Zhou; Hong Li; Shuhua Wu; Zhang Cao
Journal:  Biomed Res Int       Date:  2022-06-25       Impact factor: 3.246

9.  Characterization of Kinase Expression Related to Increased Migration of PC-3M Cells Using Global Comparative Phosphoproteome Analysis.

Authors:  Yan Gao; Yun-Sok Ha; Tae Gyun Kwon; Young-Chang Cho; Sangkyu Lee; Jun Nyung Lee
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

10.  Calponin 3 suppresses proliferation, migration and invasion of non-small cell lung cancer cells.

Authors:  Chenglin Yang; Shiping Zhu; Weifeng Feng; Xuexin Chen
Journal:  Oncol Lett       Date:  2021-07-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.